NCT04796324Phase 2Terminated

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-12-01Actual

Enrollment · participants13Actual

Source updated2026-03-12Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-20 · 3 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~60 participants (planned)~~

+ After

13 participants (actual)

Recruitment status changed

− Before

~~Suspended~~

+ After

Terminated

Check registry source

Study details

Conditions studied

Metastatic Breast Cancer

Treatments or interventions studied

Ixabepilone InjectionDrug

Primary outcomes · main study measures

measure: Clinical Benefit Rate (CBR); description: To evaluate the clinical benefit rate of ixabepilone using tumor measurements (e.g. CT or MRI etc.). One-sided comparisons of CBR between treatment and historic control will be performed, and will be repeated for subgroups defined by ER status.; timeFrame: Baseline to 24 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history